Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the pharmacokinetics (PK) and to assess safety and tolerability of a single dose of ASP3291 in subjects with ulcerative colitis.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Telsar Pharma Inc.
NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more
NCT06372613 · Ulcerative Colitis in Histologic Remission
NCT07550673 · Acute Severe Ulcerative Colitis
NCT07374471 · Ulcerative Colitis (UC)
NCT05739864 · Active Ulcerative Colitis
Advanced Clinical Research Institute
Anaheim, California
SNBL Clinical Pharmacology Center
Baltimore, Maryland
Clinical Trials of Texas, Inc.
San Antonio, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions